Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?
Venetoclax is a highly selective B-cell lymphoma-2 (BCL-2) inhibitor, which, combined with a DNA hypomethylating agent or low dose cytarabine, results…
Venetoclax is a highly selective B-cell lymphoma-2 (BCL-2) inhibitor, which, combined with a DNA hypomethylating agent or low dose cytarabine, results…
Heart failure with reduced ejection fraction (HFrEF) is a complex and progressive clinical condition characterized by dyspnea and functional impairmen…
Heart failure with reduced ejection fraction (HFrEF) is a complex and progressive clinical condition characterized by dyspnea and functional impairmen…
Eleftheria Kampouri, Patrick W Flaherty, Hu Xie, Mandeep K Sekhon, Clementine Chalal, Terry L Stevens-Ayers, Damian J Green, Jordan Gauthier, Mazyar Shadma
Key Points. Based on duration and timing of thrombocytopenia, we introduce T-ICAHT as a novel grading that expands on the existing N-ICAHT system.Severe (G
Key Points. Bridging radiotherapy prior to CAR-T was well-tolerated with minimal toxicity in this large multicenter studyComprehensive bridging radiotherap
Key Points. A phase 2 academic clinical trial of CD19 CAR T cells demonstrates durable remissions with a 1-year LFS in low disease burden groups…
Key Points. Based on duration and timing of thrombocytopenia, we introduce T-ICAHT as a novel grading that expands on the existing N-ICAHT system.Severe (G
Key Points. Maintenance romidepsin post-AHCT in an unselected population of patients with PTCL did not meet a primary efficacy endpoint.Maintenance romidep
Key Points. CAR T-cells induce a cellular and humoral immunodeficiency resulting in an initial susceptibility for bacterial and later viral infectionsSever
Key Points. No clearance of mid-cycle-marrow blasts in patients with IDH2R172-mutated AML after intensive induction, despite later achieving CRKinetics of